

## **Scripps Florida Funding Corporation Annual Report Pursuant to s. 288.955, F.S.**

### **INTRODUCTION**

Section 288.955 of the Florida Statutes created the Scripps Florida Funding Corporation (“SFFC”) to facilitate the establishment and operation of a biomedical research institution for the purposes of enhancing education and research and promoting economic development and diversity. The statute charged SFFC with the obligation to assure the compliance by The Scripps Research Institute (“Scripps Florida”) with the statute and the agreement between SFFC and Scripps Florida (the “Operating and Funding Agreement”). The statute provides that SFFC shall prepare or obtain certain reports, audits, and evaluations of Scripps Florida’s compliance with the performance expectations and disbursement conditions contained in the statute.

As of June 30, 2014, Scripps Florida met or exceeded all its job creation and capital expenditure requirements, and all funds have been released or delivered to Scripps Florida. On August 30, 2021, SFFC, having exhausted all funding required for its operations, voted unanimously to dissolve. Section 288.955, F.S., provides that in the event of the dissolution of SFFC, the Department of Economic Opportunity (“DEO”) shall be SFFC’s successor in interest and shall assume all rights, duties, and obligations of SFFC under any contract to which SFFC is then a party and under law. As such, DEO is submitting this report to the Governor, the President of the Senate, and the Speaker of the House, as required by the statute to be submitted by December 1 of each year.

This report addresses the activities and outcomes of SFFC for the fiscal year ended September 30, 2021. The Scripps Florida Annual Report addressed the activities and outcomes of Scripps Florida for the year ended June 30, 2021, and the information in the Scripps Florida Annual Report was informally updated for this report.

The statute sets forth certain information that is required to be included in this report. The information that follows has been organized to correspond to the relevant sections of the statute that address information to be included in this report. The text of the statute that describes the information to be reported in this report is set forth next to each statute section reference. For convenience, the annual report of Scripps Florida has been included as an appendix to this report, and can also be viewed at <https://www.scripps.edu/files/pdfs/campuses/florida/scientificreport2021.pdf>.

**Subsection (14) ANNUAL REPORT**

**By December 1 of each year, the corporation shall prepare a report of the activities and outcomes under this section for the preceding fiscal year. The report, at a minimum, must include:**

**Subsection (14)(a) A description of the activities of the corporation in managing and enforcing the contract with the grantee.**

As of June 30, 2014, Scripps met or exceeded all its job creation and capital expenditure requirements, and all award funds have been released or delivered to Scripps Florida. On August 30, 2021, SFFC, having exhausted all funding required for its operations, voted unanimously to dissolve. Section 288.955, F.S., provides that in the event of the dissolution of SFFC, DEO shall be SFFC's successor in interest and shall assume all rights, duties, and obligations of SFFC under any contract to which SFFC is then a party and under law. DEO has absorbed monitoring of Scripps Florida related to Scripps Florida's remaining obligations.

**Subsection (14)(b) An accounting of the amount of funds disbursed during the preceding fiscal year to the grantee.**

The final disbursement was made in December 2013 and consequently, the SBA and SFFC terminated their contract in early 2014. The total amount disbursed to Scripps Florida from 2003 to 2013 was \$351,977,664, which included interest in the amount of \$41,977,664.

**Subsection (14)(c) An accounting of the expenditures by the grantee during the fiscal year of funds disbursed under this section.**

As of June 30, 2020, there were no unspent grant funds restricted to support Scripps Florida. Therefore, there were no grant fund expenditures between July 1, 2020, and June 30, 2021.

**Subsection (14)(d) Information on the number and salary level of jobs created by the grantee, including the number and salary level of jobs created for residents of this state.**

On September 30, 2021, Scripps Florida employed 504 people. Of those, 422 were full-time employees and 82 were part-time employees, research interns, or summer interns. The breakdown of those full-time employees is shown in the table below. Of the 92 employees hired in this fiscal year (FY 2021), 35 were residents of Florida and 23 were residents of Palm Beach County.

Faculty	37
Staff Scientists	27
Research Associates	95
Scientific Support	175
Administrative Support	88
Total	422

The average salary/range for Scripps Florida employees as of June 30, 2021 is shown below.

Faculty	\$50,398 - \$340,018
Staff Scientists	\$62,566 - \$107,702
Research Associates	\$52,707 - \$72,925
Scientific Support	\$23,920 - \$192,296
Administrative Support	\$71,738 Average

Please note that certain employees of Scripps Florida may receive additional compensation and these salary ranges might not reflect their “real” or “full” salary. The ranges set forth above do not incorporate such additional compensation. For example, a faculty member who also serves as an Associate Dean of the Graduate School will receive additional compensation for that service. In this case, administrative salary is not included in their scientific salary. Additionally, only the salary received from Scripps Research is reflected in the ranges above. This is particularly apparent for the starting range salary for research associates, several of whom earn the majority of their salary from outside funding sources.

**Subsection (14)(e) Information on the amount and nature of economic activity generated through the activities of the grantee.**

According to information contained in the SFFC 2020 Annual Report:

Since 2007, the Business Development Board of Palm Beach County (“BDB”), a public-private partnership established in 1982 to be the official economic development organization for Palm Beach County, has reported 48 life science expansions and relocations to the County which have created 3,674 direct jobs and retained 519 jobs. This has resulted in over \$330 million in capital expenditures in the life sciences and healthcare industries. Scripps Florida remains a steadfast supporter of the many requests for tours and information for the BDB’s recruitment visits.

In 2019, the BDB reported that there are ten companies coming to Palm Beach County within the life science industry, creating over 350 jobs, and the organization has assisted over a dozen life science companies to grow, making direct investments of over \$100M into the local economy. A new proposed life science accelerator is planned for Jupiter, Gift of Life opened the Nation’s

first stem cell collection center in Boca Raton, and Expansion Therapeutics is creating cures for RNA-mediated diseases. Other companies that made moves or expanded in Palm Beach County included Algafeed, Alphazyme, Capzer Pharmaceuticals, Cytonics, Detraxi, Beacon of Hope CRO, 20Lighter, and Secret Sequence. The BDB also reported that the largest life sciences Series A investments in Florida for 2018-19 were in Palm Beach County, including Expansion Therapeutics and X-Vax, both exceeding \$55M each.

In June 2020, the BDB's Robert Mino, Vice President of Life Sciences, announced that 10 new life science companies have relocated to or expanded in Palm Beach County, creating more than 1,000 high-salary jobs over the past six months. Currently, 30 additional companies are planning announcements by the end of 2020, which would create 1,600 more jobs. Other updates for the sector:

- For the first time in 21 years, BioFlorida Annual Conference will be hosted in Palm Beach County. Life science leaders from around the world will see the County's innovation in-person.
- The BDB has continued "Post Doctoral Career Talks" with local academic institutes such as Scripps Florida, FAU, Lynn University, and Keiser University. This has resulted in several local hires, retaining graduated talent locally.
- A tri-county call with the State of Florida Drugs, Devices, and Cosmetics, and a dozen pharmacies, pharmaceutical manufacturers, and other stakeholders, was hosted by the BDB to prepare Florida's drug supply for the hurricane season.

In September 2020, the BDB announced that Seven Kings Holdings, Inc., is building out laboratory space within walking distance of the Scripps Research Institute, Max Planck Florida Institute for Neuroscience, and Florida Atlantic University's Jupiter Campus. The Jupiter Center for Discovery will bring much needed high-end laboratory space to Palm Beach County, a competitive edge that will attract more life science companies as they leave biotech hotspots like Cambridge, Massachusetts and Torrey Pines, California.

The BDB worked with Ray Graziotto, President and CEO of Seven Kings Holdings, on making the necessary connections and providing support through this new development. This project will create up to 25,000 square feet of new, high-end lab space with accommodations for approximately 50 researchers. More research-specific space and flexible lease terms are expected to attract early stage life science and research companies.

**Subsection (14)(f) An assessment of factors affecting the progress toward achieving the projected biotech industry cluster associated with the grantee's operations, as projected by economists on behalf of the Executive Office of the Governor.**

Since the early days of its operation in Florida, Scripps Research has produced leading-edge biomedical research that is now producing major advances in diverse medical fields, including cancer, ALS, addiction, neuroscience, autism, pain, vision, COVID-19, HIV, and more. Meanwhile, it has established a graduate program that ranks among the best in the nation in its specialties, the chemical and biological sciences. This creates a talent pipeline that is helping attract other life sciences companies to the state and region. Additionally, the institute's scientists have seeded an average of one new company per year, with many of these companies attracting millions in outside investments.

The state and county's investment in Scripps Research has thus conservatively produced an economic impact of approximately \$6.40 for each \$1 in public investment, as of August 2021, according to an updated economic impact study conducted by Cary E. Thomas, formerly Scripps Florida's Chief Information Officer, and a senior executive with extensive experience in higher education and research institution management.

Using the industry standard IMPLAN economic modeling program, which relies solely on the institute's expenditure data as its primary input, Mr. Thomas calculated the cumulative economic impact of Scripps Florida at \$3.23 billion. This figure reflected direct expenditures of \$1.42 billion, indirect expenditures of \$985 million, and induced expenditures of \$827.51 million.

The model does not take into the account the expenditure impact of related activities, including the recruitment of the Max Planck Florida Institute for Neuroscience, which Scripps Research officials facilitated, or the launch, growth, or acquisitions of Scripps Florida spinoff companies, which have attracted significant investment.

In 2021, Jupiter-and-Boston-based Expansion Therapeutics, an RNA-focused drug development company founded by Matthew Disney, chair of the Scripps Florida Department of Chemistry, attracted a Series B financing round of \$80 million. The company is advancing treatments for a type of muscular dystrophy, ALS and frontotemporal dementia, and other RNA-mediated diseases.

The 2021 fiscal year also saw the establishment of Myosin Therapeutics, founded by Scripps Florida neuroscientist Courtney Miller, with Scripps Florida Scientific Director Patrick Griffin, and synthetic chemist Theodore Kamenecka. In September, the company announced that it was awarded \$2.8M in non-dilutive funding from NIH/NIDA in a Fast Track SBIR to advance MT-110 for the treatment of methamphetamine use disorder.

**Subsection (14)(g)** A compliance and financial audit of the accounts and records of the corporation at the end of the preceding fiscal year conducted by an independent certified public accountant in accordance with the rules of the Auditor General.

SFFC voted unanimously to dissolve on August 30, 2021. On November 26, 2021, SFFC returned its unexpended balance of funds to DEO.

**Subsection (14)(h)** A description of the status of performance expectations under subsection (9) and the disbursement conditions under subsection (10).

**Subsection (9) PERFORMANCE EXPECTATIONS**

**Subsection (9)(a)** The number and dollar value of research grants obtained from the Federal Government or sources other than this state.

The table below shows each award received by Scripps Florida between October 1, 2020, and September 30, 2021. There were 89 awards valued at more than \$31 million dollars.

Grant Number	Awarding Agency	New or Renewal Award	Amount Awarded
W81XWH-20-1-0431	Department of Defense	New	\$ 53,423
BELHARRA/SFP0330	Foundations and other non-Federal grantees	New	\$ 750,000
EMD/SFP-0205	Foundations and other non-Federal grantees	New	\$ 420,000
CEREVANCE/0343	Foundations and other non-Federal grantees	New	\$ 220,466
SEPTERNA/SFP0585	Foundations and other non-Federal grantees	New	\$ 190,469
SEPTERN/SFP-0340	Foundations and other non-Federal grantees	New	\$ 184,942
IFM/SFP-0603	Foundations and other non-Federal grantees	New	\$ 181,981
ROME/SFP-0711	Foundations and other non-Federal grantees	New	\$ 179,735
LIBRA/SFP-0124	Foundations and other non-Federal grantees	New	\$ 173,554
BOUND/SFP-0371	Foundations and other non-Federal grantees	New	\$ 172,172
LOTTIE FRNCH FND	Foundations and other non-Federal grantees	New	\$ 127,000
AACR 20-40-44-HW	Foundations and other non-Federal grantees	New	\$ 76,400
CAN FELLOW	Foundations and other non-Federal grantees	New	\$ 75,000
SLOAN 2021-15597	Foundations and other non-Federal grantees	New	\$ 75,000
AHA 827718	Foundations and other non-Federal grantees	New	\$ 71,306
ACS GCI PHARMA	Foundations and other non-Federal grantees	New	\$ 50,000
BOW FDN	Foundations and other non-Federal grantees	New	\$ 45,481

<b>Grant Number</b>	<b>Awarding Agency</b>	<b>New Renewal Award</b> or	<b>Amount Awarded</b>
MOFFIT/CA227073	National Cancer Institute	Renewal	\$ 294,226
MOFFIT/CA223823	National Cancer Institute	Renewal	\$ 290,223
1R21 CA263240-01	National Cancer Institute	New	\$ 259,463
TSRI/CA262290-01	National Cancer Institute	New	\$ 184,395
5R01 CA241816-03	National Cancer Institute	Renewal	\$ 19,014
2R01 EY018139-14	National Eye Institute	Renewal	\$ 851,194
1R01 AG070719-01	National Institute of Aging	New	\$ 664,785
MAYO/P01AG062413	National Institute of Aging	Renewal	\$ 148,118
5R21 AG068887-02	National Institute of Aging	Renewal	\$ 60,236
5U19 AI149646-02	National Institute of Allergy and Infectious Diseases	Renewal	\$ 2,834,491
7P01 AI145815-02	National Institute of Allergy and Infectious Diseases	Renewal	\$ 2,319,342
4R37 AI091476-11	National Institute of Allergy and Infectious Diseases	Renewal	\$ 982,888
1R01 AI164772-01	National Institute of Allergy and Infectious Diseases	New	\$ 938,621
4R33 AI140439-04	National Institute of Allergy and Infectious Diseases	Renewal	\$ 921,796
1R01 AI167732-01	National Institute of Allergy and Infectious Diseases	New	\$ 888,631
1R01 AI156268-01	National Institute of Allergy and Infectious Diseases	New	\$ 584,460
1U01 AI163063-01	National Institute of Allergy and Infectious Diseases	New	\$ 511,877
GLADSTONE/AI1645	National Institute of Allergy and Infectious Diseases	New	\$ 511,063
JEFFERSON/AI1644	National Institute of Allergy and Infectious Diseases	New	\$ 465,447
1R56 AI165137-01	National Institute of Allergy and Infectious Diseases	New	\$ 462,500
1R21 AI151537-01	National Institute of Allergy and Infectious Diseases	New	\$ 277,500
1R21 AI154039-01	National Institute of Allergy and Infectious Diseases	New	\$ 277,500
1R21 AI158296-01	National Institute of Allergy and Infectious Diseases	New	\$ 277,500
1R21 AI157929-01	National Institute of Allergy and Infectious Diseases	New	\$ 272,626
MCW/AI155405	National Institute of Allergy and Infectious Diseases	New	\$ 270,719

Grant Number	Awarding Agency	New or Renewal Award	Amount Awarded
TEMPLE/AI164568	National Institute of Allergy and Infectious Diseases	New	\$ 223,645
HOPKINS/AI164566	National Institute of Allergy and Infectious Diseases	New	\$ 203,300
1R01 AI165137-01	National Institute of Allergy and Infectious Diseases	New	\$ 115,625
SBU/AI141592-03	National Institute of Allergy and Infectious Diseases	Renewal	\$ 94,018
SCRI/AI150472-10	National Institute of Allergy and Infectious Diseases	Renewal	\$ 73,983
EMMUNE/R44AI1652	National Institute of Allergy and Infectious Diseases	New	\$ 29,600
TSRI/AI153298-02	National Institute of Allergy and Infectious Diseases	Renewal	\$ 22,246
1R56 DK126895-01	National Institute of Diabetes and Digestive and Kidney Diseases	New	\$ 507,486
MSSM/DA048385-04	National Institute of Diabetes and Digestive and Kidney Diseases	Renewal	\$ 462,500
BWH/DK107239-05	National Institute of Diabetes and Digestive and Kidney Diseases	Renewal	\$ 288,872
TSRI/DK126730-01	National Institute of Diabetes and Digestive and Kidney Diseases	New	\$ 151,985
1F31 DK127643-01	National Institute of Diabetes and Digestive and Kidney Diseases	New	\$ 33,036
1R35 GM139604-01	National Institute of General Medical Sciences	New	\$ 549,876
1R35 GM142462-01	National Institute of General Medical Sciences	New	\$ 462,496
USC/GM137901-02	National Institute of General Medical Sciences	Renewal	\$ 68,400
UVA/GM138532-02	National Institute of General Medical Sciences	Renewal	\$ 37,286
TSRI/TR002551-04	National Institutes of Health	Renewal	\$ 74,118
TSRI/TR002551-03	National Institutes of Health	Renewal	\$ 29,294
TSRI/TR002550	National Institutes of Health	Renewal	\$ 26,442
2R01 MH108519-06	National Institute of Mental Health	Renewal	\$ 462,500
1R21 MH127734-01	National Institute of Mental Health	New	\$ 277,500
1F31 MH127958-01	National Institute of Mental Health	New	\$ 34,275
5R35 NS116846-02	National Institute of Neurological Disorders and Stroke	Renewal	\$ 1,632,852
5P01 NS099114-05	National Institute of Neurological Disorders and Stroke	Renewal	\$ 1,174,892
1R21 NS121951-01	National Institute of Neurological Disorders and Stroke	New	\$ 508,750
RUTGERS/UH3NS116	National Institute of Neurological Disorders and Stroke	Renewal	\$ 462,500



Grant Number	Awarding Agency	New or Renewal Award	Amount Awarded
1R61 NS119714-01	National Institute of Neurological Disorders and Stroke	New	\$ 351,725
JAX/5R01NS102414	National Institute of Neurological Disorders and Stroke	Renewal	\$ 300,490
TAMU/NS124198-01	National Institute of Neurological Disorders and Stroke	New	\$ 252,671
UHSP/NS126036-01	National Institute of Neurological Disorders and Stroke	New	\$ 92,500
MOFFITT/NS11965	National Institute of Neurological Disorders and Stroke	Renewal	\$ 59,432
MAYO/NS118513-02	National Institute of Neurological Disorders and Stroke	Renewal	\$ 58,257
1R61 NS119658-01	National Institute of Neurological Disorders and Stroke	New	\$ 47,803
BOSTON/NS117101	National Institute of Neurological Disorders and Stroke	Renewal	\$ 47,632
MOFFITT/NS117926	National Institute of Neurological Disorders and Stroke	New	\$ 41,649
1S10 OD030330-01	National Institutes of Health - Office of the Director	New	\$ 600,000
1S10 OD030332-01	National Institutes of Health - Office of the Director	New	\$ 485,845
1R21 AA028727-01	National Institute on Alcohol Abuse and Alcoholism	New	\$ 267,975
1R01 DC020031-01	National Institute on Deafness and Other Communication Disorders	New	\$ 462,500
NEU/DA045020-05	National Institute on Drug Abuse	Renewal	\$ 640,041
WFUHS/R01DA0484	National Institute on Drug Abuse	Renewal	\$ 347,752
SCRI/DA048036-4	National Institute on Drug Abuse	Renewal	\$ 317,934
CORNELL/DA052027	National Institute on Drug Abuse	Renewal	\$ 172,975
SCRI/DA048036-3	National Institute on Drug Abuse	Renewal	\$ 148,057
UCSD/DA047039-04	National Institute on Drug Abuse	Renewal	\$ 109,919
NSF/2026993	National Science Foundation	New	\$ 161,404
NSF/DGE 1842471	National Science Foundation	New	\$ 138,000
	Total Awards October 1, 2020 – September 30, 2021		\$ 31,727,581

Note: In the above table, amounts shown are the first-year award amount for “New” awards and the respective continuing yearly amount for “Renewal” awards.

**Subsection (9)(b)      The percentage of total research dollars received by Scripps Florida from sources other than this state which is used to conduct research activities by the grantee in this state.**

Since the state grant funds were fully expended prior to the beginning of this fiscal year, the percentage of research funding from sources other than SFFC was 100%. The total expenditure on research between October 1, 2020, and September 30, 2021, was \$61,203,286.

**Subsection (9)(c)      The number or value of patents obtained by the grantee.**

In Fiscal Year 2021 (October 1, 2020, to September 30, 2021), 13 foreign and domestic patent applications were filed, and 10 U.S. patents were issued. Since inception, 189 “families” of patent applications have been filed covering Scripps Florida technology, with each family containing one to six patent applications. No value has been assigned to the patents at this time.

**Subsection (9)(d)      The number or value of licensing agreements executed by the grantee.**

No additional license agreements were executed with respect to Scripps Florida technologies in FY 2021.

**Subsection (9)(e)      The extent to which research conducted by the grantee results in commercial applications.**

Because of the early stage of the technology being developed at Scripps Florida, no commercial applications have emerged to date. Currently, Scripps Florida is actively engaged in developing therapeutic agents suitable for a variety of diseases and indications and continues its efforts in developing novel therapeutics against SARS-CoV-2, which could benefit from accelerated development timelines. Moreover, as noted in previous Annual Reports, several research tools developed at Scripps Florida continue to be available commercially through various licensing arrangements.

**Subsection (9)(f)**

**The number of collaborative agreements reached and maintained with colleges and universities in this state and with research institutions in this state, including agreements that foster participation in research opportunities by public and private colleges and universities and research institutions in this state with significant minority populations, including historically black colleges and universities.**

Scripps Florida has developed a template entitled the Joint Cooperation Agreement (“JCA”) to encourage and support research collaborations with Florida institutions. Provisions are included to make it easier to collaborate on filing patents for jointly developed technologies and to share revenues from commercialized innovations. By executing these agreements in advance, Scripps Florida expects to streamline the scientific collaboration process between Florida organizations and Scripps Florida as they work together on biomedical research. Nine Florida institutions have currently executed this formal agreement with Scripps Florida: Florida International University, University of Florida, Florida Atlantic University, University of Central Florida, University of Miami, Florida State University, Nova Southeastern University, University of South Florida, and Max Planck Florida Institute. Scripps scientists have also participated in formal scientific meetings with colleagues at Florida foundations, colleges, and universities.

**Subsection (9)(g)**

**The number of collaborative partnerships established and maintained with businesses in this state.**

Scripps Florida continues to maintain collaborative relationships with Florida based companies: CALM Therapeutics, Dyadic International, Deluge Biotechnologies, Emmune, Expansion Therapeutics, Florida Power and Light, Opko Health, and Vova Ida Therapeutics.

CALM Therapeutics is developing novel therapeutics to treat Prader-Willi syndrome.

Deluge Biotechnologies is a Jupiter-based company founded in 2017 based on technologies from Paegel and Kodadek labs at Scripps Florida that employs DNA-encoded epitope surrogate technology to develop disease diagnostics.

A collaborative effort between scientists at Scripps Florida and Dyadic International was established to provide a complete annotation of the genome of Dyadic’s proprietary fungal organism, *Chrysosporium lucknowense* (“C1”). The knowledge gained from this effort is expected to facilitate further development of the C1 Host Technology as a robust platform for the discovery, development, and production of various materials for medical and industrial applications. Furthermore, this collaboration promotes the development of a successful biotechnology cluster in South Florida.

Emmune, previously Immunathon, was founded in 2015 in Palm Beach County to commercialize technology from Mike Farzan’s lab at Scripps Florida. The company is engaged in the development and commercialization of novel approaches for the treatment and prevention of HIV infection.

Expansion Therapeutics, based on Disney lab technology at Scripps Florida, with a research facility in Jupiter, is focused on development of therapeutics for RNA mediated diseases.

Scripps Florida is collaborating with Florida Power and Light, a Juno Beach-based utility that is the principal subsidiary of NextEra Energy Inc., to develop novel and proprietary technology which may yield cheaper and more effective ways at producing fuels and other commodities from natural gas.

Opko Health is a publicly-traded healthcare company involved in the discovery, development, and commercialization of pharmaceutical products, vaccines, and diagnostic products. Opko and Scripps Florida are currently collaborating in three major areas: the development of novel diagnostic products to detect Alzheimer’s and other diseases, the development of novel drug candidates to treat Parkinson’s Disease, and the discovery of novel antibiotics.

Vova Ida Therapeutics is a Palm Beach County-based company founded in 2013 to commercialize research from the Corinne Lasmezas lab at Scripps Florida. The company is developing drugs to treat age-related neurodegenerative diseases, such as Alzheimer’s disease.

In addition to the list above, Scripps Florida has listed other current and past business partners in pages 98 through 103.

**Subsection (9)(h) The total amount of funding received by the grantee from sources other than the State of Florida.**

Since inception through June 30, 2021, Scripps Florida has been awarded \$677,890,497 in grants and sponsored research funding from state and federal agencies (including NIH), foundations, pharmaceutical companies, and other grantors. In addition, the County of Palm Beach provided \$210 million to Scripps for construction of the permanent facility.

Funding received by Scripps Florida from sources other than SFFC for the nine months ending June 30, 2021, are set forth below:

Other Revenue Sources	\$10,018,791
Grant Awards	\$31,727,581
Contributions*	\$6,995,014

\*This amount was determined in accordance with generally accepted accounting principles. Therefore, certain non-cash items, such as promises to give, are reflected at their estimated net realizable value.

**Subsection (9)(i) The number or value of spin-off businesses created in this state as a result of commercialization of the research of the grantee.**

Florida companies that were created to benefit from licenses to technology developed primarily at Scripps Florida are described in the table below. No attempt has been made by Scripps to assign a value to these spin offs businesses, with the exception of Curna, which was purchased by Miami-based Opko Health for \$10,000,000, Envoy Therapeutics, which was purchased by Japan-based Takeda for \$140,000,000, and Padlock Therapeutics, which was purchased by New York-based Bristol-Meyers Squibb for approximately \$600,000,000.

Established	Company	Business Description	Description of License and/or Ownership
2020	Bliss Pharmaceuticals, LLC	Bliss Pharmaceuticals develops vaccines based on engineered fragments of the improved SARS-CoV-2 receptor binding domain (RBD)	Exclusive License until 06/17/2020; 20% equity until \$25M raised
2018	Synkine	Synkine is developing small molecule therapeutics for life-threatening metabolic, oncologic, and orphan diseases.	Exclusive license 11/22/2020; 3% equity upon execution; additional 4.5% upon addition of IP; maintained until \$10M raised
2015	Emmune	Emmune is developing novel approaches for the prevention and treatment of HIV infection.	Exclusive license 09/27/2019; 10% until \$10M; thereafter maintained at 5% until \$30M raised
2018	CALM Therapeutics	CALM Therapeutics is developing novel therapeutics to treat Prader-Willi syndrome.	Exclusive license 4/9/2018; 1,200,000 shares
2017	Deluge Biotechnologies	Deluge Biotechnology is focused on developing diagnostics by utilizing epitope surrogate technology with focus on tuberculosis, lung cancer and T1D.	Option Agreement 5/5/2017. Pre-negotiated license to execute Exclusive license at 2nd anniversary with 20% equity to be maintained until \$20M equity raise
2016	Expansion Therapeutics	Expansion Therapeutics is developing therapies targeting of RNA expanded sequences (e.g. Amyotrophic lateral sclerosis).	Exclusive license 12/28/2016; 1,288,522 shares

2014	Hyconix	Hyconix is developing and commercializing chemical processes and products useful in the petrochemical industry.	Exclusive license. 10/21/14; 1,000,000 shares Preferred Series A
2014	Padlock Therapeutics (acquired by Bristol-Myers Squibb 3/16)	Padlock Therapeutics is focused on autoimmune diseases, specifically the role of modified auto-antigens in triggering and maintaining these pathologies.	Exclusive license 12/5/14; \$868,953.64 payout 3/02/17
2013	Vova Ida Therapeutics	Vova Ida Therapeutics is focused on developing therapeutics for neurodegenerative diseases with protein misfolding.	Option Agreement 9/30/2013; Exclusive license 07/26/2018 with 13% equity to be maintained at 6.5% until \$20M raise
2011	Ember Therapeutics (merged with Mariel Therapeutics 3/15)	Ember Therapeutics is continuing the development of a new class of PPAR $\gamma$ binding compounds that have potent antidiabetic activity but lack the side effects associated with other PPAR $\gamma$ agonists.	Exclusive license 12/12/11; License Terminated 2/27/14; 150,000 shares
2008	Curna (acquired by Opko Health 2/11)	Curna develops therapeutics based on noncoding RNA technology.	\$314,029.20 payout 2/1/11
2007	Xcovery	Xcovery develops next generation kinase therapeutics for cancer and inflammatory diseases.	263 shares; Company is private; License terminated by failure to pay patent expenses 9/6/07

**Subsection (9)(j) The number or value of businesses recruited to this state by the grantee.**

Assigning a numerical value to business recruitment activities is difficult. Scripps Florida is extensively involved in local, state, and national efforts to promote and develop the biotech industry in Palm Beach County and the State of Florida.

**Subsection (9)(k) The establishment and implementation of policies to promote supplier diversity using the guidelines developed by the Office of Supplier Diversity under s. 287.09451 and to comply with the ordinances, enacted by the County and which are applicable to this biomedical research institution and campus located in this state.**

Supplier Diversity Mission and Vision Statement:

Scripps Research is committed to maintaining an equitable and competitive business environment. As part of this commitment, we work to develop

procedures and initiatives that will help ensure that all companies receive fair consideration. Scripps Research recognizes contractor and supplier diversity as an important component of its overall business effort and will continue to take all necessary affirmative steps to assure that small and minority businesses, women's business enterprises, and labor surplus area firms are used when possible for the procurement of goods and services.

The Scripps Florida Procurement Department, led by Mr. Erik Duffey, Director, continues to pursue opportunities to partner with the diverse business community. Scripps Florida continues to participate in county, state and national diverse supplier shows. These shows help Scripps Florida to identify diverse businesses that can provide goods and services to the institute at a competitive price. Participation in these shows has resulted in partnerships with local companies that provide furniture, pipette calibrations, refrigeration services, relocation services, dry ice services, landscaping and irrigation services, building maintenance services, printing services, shredding services, and more.

**Subsection (9)(l)      The designation by the grantee of a representative to coordinate with the Office of Supplier Diversity.**

Mr. Adrian Orozco serves in the position as the Scripps Supplier Diversity Coordinator. Mr. Orozco represents Scripps in working with small and minority business enterprises in the State of Florida and is actively involved in many state and local supplier diversity outreach programs.

**Subsection (9)(m)      The establishment and implementation of a program to conduct workforce recruitment activities at public and private colleges and universities and community colleges in this state which request the participation of the grantee.**

Scripps Florida has extended workforce recruitment efforts to Florida's higher education institutions throughout the state. A list of Institution Career Fair and Expositions attended by Scripps Florida Human Resources (and others) is shown below.

<b>University / Institution</b>	<b>Event</b>	<b>Date</b>
Carolina Cluster Career Pathway Initiative	Carolina Historically Black Colleges and Universities (HBCU) Career Talent Showcase	10/20/2020
CareerSource Palm Beach County	South Florida Healthcare and Life Sciences Virtual Job Fair	10/20/2020
Palm Beach County CareerSource	Career Source PBC Healthcare & Life Sciences Virtual Job Fair	10/20/2020
Florida Atlantic University	Florida Atlantic University Fall 2020 Careers in Life & Health Sciences	10/27/2020
Florida Department of Veterans	Project Impact (Persons of disability and Veterans)	10/29/2020
Florida Department of Veterans	Paycheck for Patriot Veterans	11/12/2020
Florida A&M University	Florida A&M University- Spring 2021 virtual ALL- Majors & Internship Expo (HBCU )	01/27/2021
University of Central Florida	University of Central Florida's Spring 2021 2-Day Virtual Career Expo	02/03/2021
Florida Atlantic University	Florida Atlantic University Virtual Career EXPO	02/10/2021
Florida State University	Florida State University STEM Career & Internship Fair	02/16/2021
Florida International University	Florida International University Virtual Career Fair Technical Majors Spring 2021	02/17/2021
Bender Consulting Services	Bender Disability Virtual Career Fair	03/21/2021
Florida International University	Florida International University Career Expo	04/08/2021
12 Public Universities	Florida Statewide Job Fair	06/10/2021
Bender Consulting Services	Disability Virtual Career Fair-Hosted by Bender Consulting Services	07/20/2021
Palm Beach Atlantic University	Palm Beach Atlantic University Fall 2021 Job/Internship/Workshop Fair	09/08/2021
University of South Florida	University of South Florida	09/17/2021
Florida State University	Florida State University Virtual STEM Career & Internship Fair	09/21/2021



University of Central Florida	University of Central Florida Fall 2021 2-Day Virtual Career Expo (Technical Day)	09/23/2021
Florida International University	Florida International University Virtual Career Fair ALL MAJORS Fall 2021	09/29/2021
University of Florida	University of Florida Virtual Technical Fair	09/30/2021

**Subsection (10) DISBURSEMENT CONDITIONS**

**Subsection (10)(a) Demonstrate creation of jobs and report on the average salaries paid.**

On September 30, 2021, Scripps Florida employed 504 people (422 full-time and 82 part-time).

**Subsection (10)(b) Beginning 18 months after the grantee’s occupancy of its permanent facility, the grantee shall annually obtain \$100,000 of non-state funding for each full-time equivalent tenured-track faculty member employed at the Florida facility.**

There were 37 tenure track faculty employed on September 30, 2021, and the total award value (the initial award amount for new awards and the annual increment for renewal awards) was \$31,727,581; therefore, in this fiscal year each Scripps Florida faculty obtained about \$857,502 in non-Florida funding. This represents 55 new grant awards worth \$15,893,662 and 34 renewal grant awards worth \$15,833,919 from the National Institutes of Health (NIH) and other awards from non-state entities other than NIH. See subsection (9)(a) for a complete list of awards.

**Subsection (10)(c) No later than 3 years after the grantee’s occupancy of its permanent facility, the grantee shall apply to the relevant accrediting agency for accreditation of its Florida graduate program.**

The re-accreditation of the Scripps Florida Graduate Program was initially completed in early 2011, approximately two years after Scripps Florida occupied its permanent facility. The graduate program was re-accredited in February 2020.

**Subsection (10)(d) The grantee shall purchase equipment for its Florida facility as scheduled in its contract with the corporation.**

The total cost of equipment purchased by Scripps Florida from inception through contract year end January 29, 2013, was \$53,895,431, and thus the requirement was fully satisfied.

**Subsection (10)(e) No later than 18 months after occupying its permanent facility, the grantee shall establish a program for qualified graduate students from Florida universities permitting them access to the facility for doctoral, thesis-related research.**

The Ph.D. program at Scripps Florida campus was established in 2005 as part of Scripps Research Skaggs Graduate School in Chemical and Biological Sciences, well ahead of the September 2010 deadline, which was 18 months after the anticipated occupancy of the permanent facility.

**Subsection (10)(f) No later than 18 months after occupancy of the permanent facility, the grantee shall establish a summer internship for high school students.**

The Education Outreach and Community Engagement (EOCE) Programs at Scripps Florida were established in 2005 (four years before the occupation of the permanent facility), thanks to the great generosity of the William R. Kenan, Jr. Charitable Trust, to benefit the Palm Beach Community and the trainees. The High School Student Summer Internship Program (Kenan Fellows) is one of many initiatives implemented by Scripps Florida EOCE Programs. These initiatives strongly support Palm Beach County's elementary, middle, and high school students, as well as teachers and other members of the community. Throughout the years, the program has evolved to also include outreach initiatives for undergraduate students, especially those attending Florida colleges and Floridians who move away for college. Lastly, Scripps Florida graduate students and postdoctoral fellows have benefited from the EOCE Programs by obtaining science communication and teaching skills as well as mentoring experience. The goals of Scripps Florida EOCE Programs are to promote careers in biomedical research in younger generations, to create awareness in the community about the importance of supporting basic scientific research and drug discovery, and to train the next generation of scientists.

**Subsection (10)(g) No later than 3 years after occupancy of the permanent facility, the grantee shall establish a research program for middle and high school teachers.**

These programs were established in 2005. The permanent facility was occupied in 2009.

**Subsection (10)(h) No later than 18 months after occupancy of the permanent facility, the grantee shall establish a program for adjunct professors.**

Many current Scripps Florida Faculty have received adjunct faculty appointments with the University of Florida, University of Miami, and/or Florida Atlantic University. Such adjunct appointments are intended to provide a mechanism for graduate students enrolled in Florida research universities to collaborate with, to be co-mentored by, and to perform research in the laboratories of a Scripps Florida faculty member. A mechanism has been established for faculty members at Florida institutions who have established collaborative research programs with Scripps Florida faculty to be appointed to an Adjunct Professor position. The process is initiated by a Scripps Florida faculty member who submits a nomination to his/her department chair. If the chair concurs, the chair submits the nomination to the Office of the President for review and approval.

**Subsection (10)(i) No later than 6 months after commissioning its high throughput technology, the grantee shall establish a program to allow open access for qualified science projects.**

Scripps Florida initiated the “Access to Technologies” program in January 2006 to invite scientists from Florida universities and other academic research institutions to use state-of-the-art screening technologies at Scripps Florida’s facilities in Jupiter for qualifying projects. An additional “Core” platform is now available at the Scripps Florida facility that combines basic research with advanced technology.

**Subsection (10)(j) Beginning June 2004, the grantee shall commence collaborative efforts with Florida public and private colleges and universities and shall continue cooperative collaboration through the term of the agreement.**

On-going and new scientific collaborations between Scripps Florida scientists and colleagues from Florida colleges, universities, and local companies were commenced in 2005 and have continued to present.

**Subsection (10)(k) Beginning 18 months after the grantee occupies the permanent facility, the grantee shall establish an annual seminar series featuring a review of the science work done by the grantee and its collaborators at the Florida facility.**

Collaborative seminars feature prominent Florida-based speakers from the academic, biotechnology, or pharmaceutical communities and focus on topics within the broad fields of biomedical science, advanced technologies applied to biomedical research, drug discovery, and energy. External seminars are part of the institute series, inviting prominent researchers from national and

international institutions to speak. Both serve as a major foundation for creating knowledge- and technology-sharing opportunities, team building, and collaborations among biomedical researchers between Scripps Florida, Florida, and other research and academic institutions and companies. The sessions are open to interested professionals within the Scripps Florida and Florida scientific communities. Many of the California-based seminars are live-cast to the Florida campus.

**Subsection (10)(l) Beginning June 2004, the grantee shall commence collaboration efforts with the Office of Tourism, Trade, and Economic Development (OTTED) by complying with reasonable requests for cooperation in economic development efforts in the biomed/biotech industry. No later than July 2004, the grantee shall designate a person who shall be charged with assisting in these collaborative efforts.**

The grantee currently complies with reasonable requests for cooperation in economic development efforts in the biomed/biotech industry as requested by DEO, the successor-in-interest to OTTED. As of 2020, Mr. Doug Bingham is the Scripps Florida designee to assist DEO.